Theravance Biopharma (TBPH) Shares Outstanding (Weighted Average) (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $51.3 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $51.3 million, up 3.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.3 million (up 3.16% YoY), and the FY2025 annual result was $50.3 million, up 3.01% from the prior year.
• Shares Outstanding (Weighted Average) rose to $51.3 million in Q1 2026 per TBPH's latest filing, from $50.3 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $75.8 million in Q2 2022 and troughed at $48.3 million in Q1 2024.
• A 5-year average of $57.5 million and a median of $51.3 million in 2026 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) increased 16.67% in 2022, then tumbled 30.81% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $73.6 million in 2022, then slipped by 24.85% to $55.3 million in 2023, then fell by 11.67% to $48.8 million in 2024, then rose by 3.01% to $50.3 million in 2025, then advanced by 1.91% to $51.3 million in 2026.
• Business Quant data shows TBPH's Shares Outstanding (Weighted Average) at $51.3 million in Q1 2026, $50.3 million in Q4 2025, and $50.1 million in Q3 2025.